HAS opinions and decisions
La fiche de bon usage du médicament intitulée « Xolair (omalizumab) dans le traitement de l’asthme sévère», ci-jointe, est adoptée.
See also
HAS opinions and decisions
17/11/2017
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
daSryGBf4rkv3ALn